Blueprint Medicines Releases First Corporate Responsibility Report

— Report Highlights Efforts to Deliver Lasting Value to Patients and Communities, Foster a Diverse and Empowered Workforce, and Operate with Exceptional Integrity —

CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC) today released its first corporate responsibility report, highlighting its long-standing commitment to delivering lasting value to patients with cancer and blood disorders, as well as than to the communities in which it operates. The report, which formalizes the company’s efforts to track and report on environmental, social and governance (ESG) standards and initiatives, includes summaries and performance measures that demonstrate its goal-oriented culture and business practices. socially responsible.

“Since we began operations just over a decade ago, Blueprint Medicines has grown into a leading precision therapy company, fueled by our deep sense of mission to drive scientific innovation and deliver life-changing treatments for patients, as well as positively impacting the multitude of people and communities we touch along the way,” said Kate Haviland, CEO of Blueprint Medicines. “As we continue to grow our business, we are committed to being a force for good, and our first corporate responsibility report is an important step towards that goal by providing transparency about our ongoing efforts as well as a basis for future progress.”

The report summarizes the company’s activities in five interconnected areas, including patient access and community engagement, research and development, people and culture, environmental sustainability, governance and integrity, and adopts the accounting standards for the biotechnology and pharmaceutical industry of the Sustainability Accounting Standards Board ( SASB ). The report was developed by a cross-functional corporate responsibility task force under the direction of the management team and under the oversight of the Nominating and Corporate Governance Committee of Blueprint Medicines’ Board of Directors. It is available for download at

About Blueprint Medications

Blueprint Medicines is a global precision therapy company inventing life-changing therapies for people with cancer and blood disorders. Applying a precise yet agile approach, we create drugs that selectively target genetic factors, with the goal of staying ahead through disease stages. Since 2011, we have leveraged our research platform, including our molecular targeting expertise and world-class drug design capabilities, to rapidly and reproducibly translate science into a wide range of precision therapies. Today, we provide approved medicines directly to patients in United States and Europe, and we are advancing several programs globally for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding strategy, objectives and anticipated milestones, plans for business and direction of Blueprint Medicines. The words “aim”, “may”, “will”, “could”, “do”, “should”, “expect”, “plan”, “anticipate”, “intend”, ” believes”, “estimates”, “predicts”, “projects”, “potential”, “continues”, “targets” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. ‘identification. All forward-looking statements contained in this report are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and factors that may cause actual events or results to differ materially. of those expressed or implied by the forward-looking statements. contained in this report, including but not limited to the risks and uncertainties associated with the impact of the COVID-19 pandemic on Blueprint Medicines business, operations, strategy, objectives and planned milestones , including Blueprint Medicines’ ongoing and planned research and discovery activities, ability to conduct ongoing and planned clinical trials, deliver current or future drug candidates, deliver current or future approved products commercially, and to launch, market and sell current or future approved products; Blueprint Medicines’ ability and plans to continue to establish and expand a commercial infrastructure and to successfully launch, market and sell current or future approved products; Blueprint Medicines’ ability to successfully expand approved indications for AYVAKIT/AYVAKYT and GAVRETO or obtain marketing approval for AYVAKIT/AYVAKYT in other geographies in the future; delay in any ongoing or planned clinical trials or development of Blueprint Medicines’ current or future drug candidates; advancing Blueprint Medicines from multiple early-stage efforts; the ability of Blueprint Medicines to successfully demonstrate the safety and efficacy of its drug candidates and to obtain approval of its drug candidates on a timely basis, if at all; preclinical and clinical results of Blueprint Medicines’ drug candidates, which may not support the further development of these drug candidates, either as monotherapies or in combination with other agents, or may impact the expected timing of data or regulatory submissions; timing of initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines’ ability to obtain, maintain and enforce patent and other intellectual property protections for AYVAKIT/AYVAKYT, GAVRETO or any drug candidates it develops; Blueprint Medicines’ ability to develop and commercialize companion diagnostic tests for AYVAKIT/AYVAKYT, GAVRETO or any of its current and future drug candidates; Blueprint Medicines’ ability to successfully expand its operations, research platform and pipeline of therapeutic candidates, and the timing and costs thereof; Blueprint Medicines’ ability to realize the expected benefits of its executive transition plan; and the success of Blueprint Medicines’ current and future collaborations, acquisitions, partnerships or licensing agreements. These and other risks and uncertainties are described in more detail in the section titled “Risk Factors” in Blueprint Medicines’ filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines’ most recent annual report. Blueprint Medicines on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings Blueprint Medicines has made or may make with the SEC in the future. All forward-looking statements contained in this report represent the views of Blueprint Medicines only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines expressly disclaims any obligation to update forward-looking statements.

SOURCE Blueprint Medicines Corporation

Comments are closed.